SCHEMBL5135694

SCHEMBL5135694

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC)c(F)c1)CC1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.44
DRD4 P21917 6/20 0.35
DRD1 P21728 5/20 0.35
HTR2C P28335 5/20 0.35
DRD3 P35462 5/20 0.35
DRD5 P21918 2/20 0.35
TP53 P04637 1/20 0.34
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PDE5A O76074 2/20 0.34
PSEN1 P49768 4/20 0.33
PSEN2 P49810 4/20 0.33
APH1B Q8WW43 4/20 0.33
NCSTN Q92542 4/20 0.33
APH1A Q96BI3 4/20 0.33
PSENEN Q9NZ42 4/20 0.33
DRD2 P14416 3/20 0.33
ALDH1A1 P00352 2/20 0.33
POLB P06746 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648140 0.93 C5AR1 (0.44) C5AR1DRD4DRD1HTR2CDRD3
SCHEMBL651135 0.92 C5AR1 (0.41) C5AR1DRD4DRD1HTR2CDRD3
SCHEMBL5135166 0.91 C5AR1 (0.45) C5AR1ALDH1A1HDAC1CRHR1KDM4E
SCHEMBL5137096 0.91 C5AR1 (0.42) C5AR1DRD4DRD1HTR2CDRD3
SCHEMBL649094 0.89 C5AR1 (0.43) C5AR1ALDH1A1HDAC1CRHR1KDM4E
SCHEMBL651431 0.89 C5AR1 (0.43) C5AR1PDE5AALDH1A1HDAC1CRHR1
SCHEMBL5136024 0.89 C5AR1 (0.41) C5AR1TP53GAASMN1; SMN2POLB
SCHEMBL5136497 0.89 C5AR1 (0.41) C5AR1TP53ALDH1A1KDM4ECYP3A4
SCHEMBL651006 0.88 C5AR1 (0.42) C5AR1ALDH1A1HDAC1CRHR1KDM4E
SCHEMBL649931 0.88 C5AR1 (0.47) C5AR1TP53GAASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed